Scholarlink

Background <p>Targeting Claudin-18 isoform 2 (CLDN18.2) improves survival in CLDN18.2 positive advanced gastric cancer and similar trials on metastatic pancreatic ductal adenocarcinoma (PDAC) are ongoing. Here, we aimed to assess the prevalence of CLDN18.2 positivity in resected PDAC including its association with overall survival (OS).</p> Methods <p>Immunohistochemical analysis on paraffin-embedded primary tumors and lymph node metastases was performed from patients who underwent curative-intent PDAC resection at four centers in Sweden and Finland. In addition, survival outcomes were assessed.</p> Results <p>In total, 599 primary tumors and 197 lymph nodes were analyzed. CLDN18.2 positivity was observed in 138 of 599 of primary tumors (23%) and 35 of 197 metastatic lymph nodes (17.8%). CLDN18.2 positivity in primary tumors was associated with higher tumor grade (<i>p</i> = 0.016). Median OS was longer in patients with CLDN18.2-positive tumors (27.7 vs. 21.1 months). Adjusted analysis identified CLDN18.2 positivity as an independent prognostic variable for OS (hazard ratio 0.79; 95% confidence interval 0.64–0.98).</p> Conclusions <p>CLDN18.2 is expressed in 23% of primary PDAC tumours, indicating its potential to be used as a therapeutic target in a significant proportion of PDAC patients, and its expression is associated with improved OS in resected PDAC, supporting its role as a prognostic marker.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月14日

查看全文
  • Jun Yoshino,
  • Hakon Blomstrand,
  • Sebastian Fjellander,
  • Johan Svensson,
  • Asif Halimi,
  • Ella Kesti,
  • Hanna Seppänen,
  • Caroline Vilhav,
  • Daniel Öhlund,
  • Caj Haglund,
  • Nils O. Elander,
  • Peter Naredi,
  • Malin Sund,
  • Oskar Franklin

摘要

Background

Targeting Claudin-18 isoform 2 (CLDN18.2) improves survival in CLDN18.2 positive advanced gastric cancer and similar trials on metastatic pancreatic ductal adenocarcinoma (PDAC) are ongoing. Here, we aimed to assess the prevalence of CLDN18.2 positivity in resected PDAC including its association with overall survival (OS).

Methods

Immunohistochemical analysis on paraffin-embedded primary tumors and lymph node metastases was performed from patients who underwent curative-intent PDAC resection at four centers in Sweden and Finland. In addition, survival outcomes were assessed.

Results

In total, 599 primary tumors and 197 lymph nodes were analyzed. CLDN18.2 positivity was observed in 138 of 599 of primary tumors (23%) and 35 of 197 metastatic lymph nodes (17.8%). CLDN18.2 positivity in primary tumors was associated with higher tumor grade (p = 0.016). Median OS was longer in patients with CLDN18.2-positive tumors (27.7 vs. 21.1 months). Adjusted analysis identified CLDN18.2 positivity as an independent prognostic variable for OS (hazard ratio 0.79; 95% confidence interval 0.64–0.98).

Conclusions

CLDN18.2 is expressed in 23% of primary PDAC tumours, indicating its potential to be used as a therapeutic target in a significant proportion of PDAC patients, and its expression is associated with improved OS in resected PDAC, supporting its role as a prognostic marker.